Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2026
Reporting Period: Event date February 12, 2026; Signed February 19, 2026
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document reports a specific corporate event rather than periodic financial performance.
Material Changes
- Termination of Material Definitive Agreement: On February 12, 2026, the Binding Term Sheet dated June 17, 2025, between Processa Pharmaceuticals, Inc. and Intact Therapeutics regarding the asset PCS12852 expired.
- Outcome: No definitive license agreement was executed, and no related amendment to the License Agreement with Yuhan Corporation was entered into.
- Future Obligations: Neither party retains additional obligations under the expired Term Sheet.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the termination of the agreement. The primary contingency noted is the cessation of the proposed licensing arrangement for PCS12852 with Intact Therapeutics.
Investor Verification Checklist
- Verify the status of the PCS12852 asset and whether Processa intends to pursue other licensing partners.
- Confirm if the expiration of the Term Sheet impacts the existing License Agreement with Yuhan Corporation.
- Review subsequent press releases or filings for any new strategic developments regarding the PCS12852 program.
- Check the company's most recent 10-K or 10-Q for the latest financial position, as this 8-K contains no financial data.